基于光的分子工具,精确监测和操作β-腺素受体
Ignazzitto Maria Tindara1, Gómez-Santacana Xavier1, Llebaria Amadeu1
1Laboratory of Medicinal Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Barcelona, Catalonia, Spain.
Medicinal research reviews
|October 22, 2025
概括
基于光的工具精确地控制和监测β-腺受体 (β-ARs),G蛋白结合受体对于调节身体功能至关重要. 这项研究提高了对β-AR和相关疾病的理解.
科学领域:
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
- 生物物理学的生物物理.
背景情况:
- β-腺受体 (β-ARs) 是关键的G蛋白合受体 (GPCRs),调节心血管,代谢和神经功能.
- 了解β-AR信号对于治疗相关疾病至关重要.
研究的目的:
- 审查基于光的分子工具,以精确的时间空间控制β-ARs.
- 突出光交换性联体和光学生物传感在GPCR研究中的实用性.
主要方法:
- 利用光和生物发光来实时监测受体活性.
- 采用光药学和光遗传学来对受体功能的外部调制.
- 开发和应用可光切换的配体,用于可逆控制β-ARs.
主要成果:
- 基于光的工具提供了对β-ARs的高精度和时空控制.
- 可光切换的配体使得可逆的开/关控制受体活动.
- 结合光学生物传感和光药理学,最大限度地减少研究GPCR动态的干扰.
结论:
- 这些先进的技术显著提高了GPCR信号动态的分析.
- 光学工具的整合为β-上腺受体研究提供了一个强大的框架.
- 开辟了针对β-上腺受体相关疾病的有针对性的治疗干预措施的新途径.
相关概念视频
Adrenergic Receptors: β Subtype
3.5K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.5K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.3K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.3K
Adrenergic Agonists: Direct-Acting Agents
2.6K
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
2.6K
Adrenergic Receptors: ɑ Subtype
2.7K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
2.7K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K


